Cargando…

Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota

Dyslipidemia is a multifaceted condition with various genetic and environmental factors contributing to its pathogenesis. Further, this condition represents an important risk factor for its related sequalae including cardiovascular diseases (CVD) such as coronary artery disease (CAD) and stroke. Eme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flaig, Brandon, Garza, Rachel, Singh, Bhavdeep, Hamamah, Sevag, Covasa, Mihai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823358/ https://www.ncbi.nlm.nih.gov/pubmed/36615885 http://dx.doi.org/10.3390/nu15010228

Ejemplares similares

Gut Microbiota Restores Central Neuropeptide Deficits in Germ-Free Mice
por: Hamamah, Sevag, et al.
Publicado: (2022)

Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling
por: Hamamah, Sevag, et al.
Publicado: (2022)

Impact of Nutrition, Microbiota Transplant and Weight Loss Surgery on Dopaminergic Alterations in Parkinson’s Disease and Obesity
por: Hamamah, Sevag, et al.
Publicado: (2022)

Dietary Fat Modulation of Gut Microbiota and Impact on Regulatory Pathways Controlling Food Intake
por: Hamamah, Sevag, et al.
Publicado: (2023)

Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols
por: Hamamah, Sevag, et al.
Publicado: (2022)

Reduced Striatal Dopamine Transporter Availability and Heightened Response to Natural and Pharmacological Stimulation in CCK-1R-Deficient Obese Rats
por: Hamamah, Sevag, et al.
Publicado: (2023)

Do Diet and Dietary Supplements Mitigate Clinical Outcomes in COVID-19?
por: Singh, Bhavdeep, et al.
Publicado: (2022)

Intestinal Sensing by Gut Microbiota: Targeting Gut Peptides
por: Covasa, Mihai, et al.
Publicado: (2019)

Gut Microbiota and Complications of Type-2 Diabetes
por: Iatcu, Camelia Oana, et al.
Publicado: (2021)

Do Gut Microbes Taste?
por: Leung, Ryan, et al.
Publicado: (2021)

Microbiota Transplant in the Treatment of Obesity and Diabetes: Current and Future Perspectives
por: Napolitano, Michael, et al.
Publicado: (2020)

Gut microbiota is a potential goalkeeper of dyslipidemia
por: Lei, Lirong, et al.
Publicado: (2022)

Increased Oral Detection, but Decreased Intestinal Signaling for Fats in Mice Lacking Gut Microbiota
por: Duca, Frank A., et al.
Publicado: (2012)

Ecological change of the gut microbiota during pregnancy and progression to dyslipidemia
por: Yang, Xu, et al.
Publicado: (2023)

The Role of Gut Microbiota and Its Produced Metabolites in Obesity, Dyslipidemia, Adipocyte Dysfunction, and Its Interventions
por: Zwartjes, Max S. Z., et al.
Publicado: (2021)

Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota
por: Maslennikov, Roman, et al.
Publicado: (2023)

Clindamycin as an Alternative Option in Optimizing Periodontal Therapy
por: Luchian, Ionut, et al.
Publicado: (2021)

Cytidine Alleviates Dyslipidemia and Modulates the Gut Microbiota Composition in ob/ob Mice
por: Niu, Kaixia, et al.
Publicado: (2023)

Functional roles of the microbiota-gut-brain axis in Alzheimer’s disease: Implications of gut microbiota-targeted therapy
por: Zhong, Si-Ran, et al.
Publicado: (2021)

Nutritional Interventions Targeting Gut Microbiota during Cancer Therapies
por: Rinninella, Emanuele, et al.
Publicado: (2021)

Effect of gut microbiota in the colorectal cancer and potential target therapy
por: Li, Junchuan, et al.
Publicado: (2022)

The Gut Microbiota in Kidney Transplantation: A Target for Personalized Therapy?
por: García-Martínez, Yuselys, et al.
Publicado: (2023)

Gut microbiota, an emergent target to shape the efficiency of cancer therapy
por: Kouidhi, Soumaya, et al.
Publicado: (2023)

Treatment of dyslipidemia
por: Tonkin, Andrew, et al.
Publicado: (2014)

Associations of gut microbiota with dyslipidemia based on sex differences in subjects from Northwestern China
por: Guo, Lei, et al.
Publicado: (2022)

Role of the Gut in Diabetic Dyslipidemia
por: Stahel, Priska, et al.
Publicado: (2020)

New hope for Parkinson's disease treatment: Targeting gut microbiota
por: Fan, Hong‐Xia, et al.
Publicado: (2022)

Treatment of dyslipidemia in the elderly
por: Shao, Hong, et al.
Publicado: (2011)

Advances in Treatment of Dyslipidemia
por: Dybiec, Jill, et al.
Publicado: (2023)

Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment
por: Pouncey, Anna Louise, et al.
Publicado: (2018)

Cholesterol: The Good, the Bad, and the Ugly – Therapeutic Targets for the Treatment of Dyslipidemia
por: Elshourbagy, Nabil A., et al.
Publicado: (2014)

A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
por: Kim, Kyuho, et al.
Publicado: (2022)

Dyslipidemia in Obesity: Mechanisms and Potential Targets
por: Klop, Boudewijn, et al.
Publicado: (2013)

CAR-T Cell Therapy and the Gut Microbiota
por: Asokan, Sahana, et al.
Publicado: (2023)

Gut Microbiota as Potential Therapeutic Target for the Treatment of Cow’s Milk Allergy
por: Canani, Roberto Berni, et al.
Publicado: (2013)

Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options
por: Panebianco, Concetta, et al.
Publicado: (2023)

Cardiovascular Diseases of Developmental Origins: Preventive Aspects of Gut Microbiota-Targeted Therapy
por: Hsu, Chien-Ning, et al.
Publicado: (2021)

Detection of Biological Molecules Using Nanopore Sensing Techniques
por: Șoldănescu, Iuliana, et al.
Publicado: (2023)

Probiotics: How Effective Are They in the Fight against Obesity?
por: Mazloom, Kiran, et al.
Publicado: (2019)

Bempedoic acid for the treatment of dyslipidemia
por: Marrs, Joel C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i2emge9cfujmu3060ph7sjl7nq